Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06376396 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

Study acronym: NeuroSolve
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: Dario Scaramuzzi to R-Evolution Worldwide S.r.l. Impresa Sociale
    • Primary completion date: Nov 2025 to Dec 2025
    • Start date: May 2024 to Jun 2024
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis.
Trial Details
NCT Number NCT06376396
Lead Sponsor R-Evolution Worldwide S.r.l. Impresa Sociale
Collaborators: Muhimbili University of Health and Allied Sciences, National Institute for Medical Research, Tanzania, Sokoine University of Agriculture, University of Zambia, University Ghent
Conditions
(from sponsor)		 Neurocysticercosis
Related terms Epilepsy, Neglected Diseases, Neurocysticercosis
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov